Gene Therapy Shows Promise for Treating Vision Loss in Dogs

A rare inherited condition affecting vision, linked to faulty copies of the CaBP4 gene, leads to poor eyesight from childhood. This gene produces a protein essential for chemical signaling in the retina.

Interestingly, this condition also impacts dogs. While researching potential treatments for them, scientists have stumbled upon a therapy that could be groundbreaking.

In a study published in Molecular Therapy Advances, a team from Michigan State University reported that a single-dose gene therapy not only halted the progression of blindness in dogs but also repaired damaged connections in their eyes.

This raises exciting possibilities: the notion that nerve cells in mammals can be repaired, which many had thought was impossible before.

“We demonstrated three distinct structural changes supporting plasticity in the adult retina,” said Billie Beckwith-Cohen, a veterinary ophthalmologist at Michigan State.

“Not only were new components introduced, but existing abnormalities were also corrected.”

Identifying the CaBP4 gene as responsible for vision loss in whippet dogs, researchers injected the retinas of affected dogs with a harmless virus carrying a functional copy of the gene.

The therapy led to considerable improvements in the dogs’ vision, particularly in low-light situations, where the lack of the CaBP4 protein is most impactful.

Additionally, the treated areas of the retina exhibited less degradation, while the outer plexiform layer (OPL) that houses essential visual connections expanded significantly, along with the synaptic ribbons in the eye’s light-sensing cells.

The OPL’s growth and the development of synaptic ribbons tend to be impaired when the CaBP4 gene is faulty, which researchers liken to flaws in a building blueprint.

“We can think of mutations in the retinal gene as typos in a blueprint that render the instructions unclear, leading to design flaws and ultimately, vision loss,” Beckwith-Cohen remarked. “Our therapy essentially offers new instructions for the mistyped segment, akin to an editor correcting text.”

This study is the culmination of a decade’s worth of research into such eye conditions. While it remains uncertain whether the same therapeutic approach would succeed in humans, the researchers are optimistic about its potential application.

“Our findings indicate that gene therapy can not only restore retinal function but also promote a nearly normal anatomical arrangement in the retina’s OPL,” the researchers stated in their paper.

This recovery involves the expansion of a layer that didn’t develop normally during retinal maturation, along with the maturation of synaptic features such as ribbon elongation, thereby supporting the structural integrity of the retinal neural network into adulthood.

Even though the CaBP4 gene condition is rare in both humans and dogs, researchers believe that this work could pave the way for innovative strategies to repair damaged neural networks and treat various conditions.

Remarkably, even after noticeable growth inhibition and damage to nerve cell connections, evidence of rewiring among nerve cells emerged. The positive effects of the therapy were sustained for up to three years post-treatment in this study.

Now that we know new neural connections can form in the retina, there are numerous research avenues to pursue, particularly regarding the role of calcium signaling (which CaBP4 manages) in cell communication within the eye.

In recent years, encouraging advancements have been made in vision restoration treatments, such as activating dormant cells and safeguarding photoreceptors, and this new research adds to that growing body of work.

“Our results show restoration of visual function in dogs with severe electrophysiologic and synaptic dysfunction,” noted the researchers.

“We have shown that the OPL of the retina exhibits significant plasticity, with synaptic ribbons capable of maturation and elongation following gene augmentation therapy, even into adulthood.”

The research has been published in Molecular Therapy Advances.